Congo Ebola Trial Enrolls First Patient Amid 438 Deaths

For healthcare leaders, this trial is a masterclass in outbreak response under duress. The launch inside a busy treatment center in Bunia—juggling ambulance arrivals, protective equipment protocols, and data collection—exposes systemic weaknesses that demand attention well beyond the current emergency. It underscores why investing in health system resilience and digital tools is as critical as the drugs themselves.

In early July 2026, a landmark clinical trial quietly began in eastern Congo's conflict-ravaged Ituri province, offering a fragile strand of hope to residents caught in the grip of an unusual Ebola outbreak. For the first time, researchers are systematically evaluating treatments specifically for Bundibugyo ebolavirus, a lesser-known species that has no licensed vaccines or therapies. The outbreak, already claiming 438 lives among more than 1,400 confirmed cases according to WHO Director-General Tedros Adhanom Ghebreyesus, has exposed a critical gap in the global health arsenal. The trial, led by Congo's INRB, Oxford University, the Antwerp Institute of Tropical Medicine, and other partners, will test Gilead's remdesivir—a broad-spectrum antiviral that gained fame during the COVID-19 pandemic—and MBP134, an experimental pan-ebolavirus antibody cocktail, as well as a combination of the two. Enrollment of the first participant was confirmed on July 2 at the Ebola treatment center inside Bunia's Evangelical Medical Center, a facility under constant ambulance sirens and the muffled bustle of healthcare workers in full protective gear.

“

Yet the stakes are immense: without proven treatments, case fatality rates could hover near 30% or higher, as seen in previous Bundibugyo episodes.

The study's launch is as much a testament to scientific resolve as it is a grim reflection of the region's reality. Eastern Congo has long been a crucible of humanitarian emergency, and this outbreak adds to multiple health crises. The Bundibugyo virus was first identified in 2007 in Uganda, and its reappearance now has surprised epidemiologists. Unlike the Zaire strain that caused the 2014-2016 West African catastrophe and the 2018-2020 Congolese outbreaks, Bundibugyo has historically caused smaller, self-limiting clusters. The current surge suggests either a shift in transmission dynamics or widespread under-detection. Amid this backdrop, the trial's design is ambitious: a 28-day survival endpoint, with a second phase planned for pre-exposure prophylaxis among healthcare workers and close contacts, as noted by Professor Yap Boum of the Africa CDC. This dual-phase approach acknowledges the pattern of nosocomial spread that has ravaged past Ebola responses, and it aligns with a broader trend in outbreak research to concurrently test therapeutic and preventive strategies.